111 related articles for article (PubMed ID: 38738472)
21. Comprehensive quantifications of tumour microenvironment to predict the responsiveness to immunotherapy and prognosis for paediatric neuroblastomas.
Song M; Sun Y; Hu Y; Wang C; Jin Y; Liu Y; Da Y; Zhao Q; Zheng R; Li L
Int Immunopharmacol; 2024 May; 133():112145. PubMed ID: 38691920
[TBL] [Abstract][Full Text] [Related]
22. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
[TBL] [Abstract][Full Text] [Related]
23. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
[TBL] [Abstract][Full Text] [Related]
24. Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments.
Fuchs D; Christofferson R; Stridsberg M; Lindhagen E; Azarbayjani F
J Transl Med; 2009 Mar; 7():16. PubMed ID: 19284605
[TBL] [Abstract][Full Text] [Related]
25. Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation.
Alshebremi M; Tomchuck SL; Myers JT; Kingsley DT; Eid S; Abiff M; Bonner M; Saab ST; Choi SH; Huang AY
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553183
[TBL] [Abstract][Full Text] [Related]
26. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment.
Mehdizadeh R; Shariatpanahi SP; Goliaei B; Rüegg C
Sci Rep; 2023 Apr; 13(1):5875. PubMed ID: 37041172
[TBL] [Abstract][Full Text] [Related]
27. Impaired Antitumor Immune Response in
Kacher J; Manches O; Aspord C; Sartelet H; Chaperot L
Cancer Res Commun; 2022 Jul; 2(7):577-589. PubMed ID: 36923280
[TBL] [Abstract][Full Text] [Related]
28. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.
Tan YS; Sansanaphongpricha K; Xie Y; Donnelly CR; Luo X; Heath BR; Zhao X; Bellile E; Hu H; Chen H; Polverini PJ; Chen Q; Young S; Carey TE; Nör JE; Ferris RL; Wolf GT; Sun D; Lei YL
Clin Cancer Res; 2018 Sep; 24(17):4242-4255. PubMed ID: 29769207
[No Abstract] [Full Text] [Related]
29. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
[TBL] [Abstract][Full Text] [Related]
30. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
31. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
32. Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.
Chakrabarti L; Morgan C; Sandler AD
PLoS One; 2015; 10(6):e0129237. PubMed ID: 26079374
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
34. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
[TBL] [Abstract][Full Text] [Related]
35. High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy.
Eranki A; Srinivasan P; Ries M; Kim A; Lazarski CA; Rossi CT; Khokhlova TD; Wilson E; Knoblach SM; Sharma KV; Wood BJ; Moonen C; Sandler AD; Kim PCW
Clin Cancer Res; 2020 Mar; 26(5):1152-1161. PubMed ID: 31615935
[TBL] [Abstract][Full Text] [Related]
36. Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism.
Chen HM; Sun L; Pan PY; Wang LH; Chen SH
Cancer Immunol Immunother; 2021 Dec; 70(12):3435-3449. PubMed ID: 33877384
[TBL] [Abstract][Full Text] [Related]
37.
Yogev O; Almeida GS; Barker KT; George SL; Kwok C; Campbell J; Zarowiecki M; Kleftogiannis D; Smith LM; Hallsworth A; Berry P; Möcklinghoff T; Webber HT; Danielson LS; Buttery B; Calton EA; da Costa BM; Poon E; Jamin Y; Lise S; Veal GJ; Sebire N; Robinson SP; Anderson J; Chesler L
Cancer Res; 2019 Oct; 79(20):5382-5393. PubMed ID: 31405846
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
[TBL] [Abstract][Full Text] [Related]
39. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
40. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]